Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • The 2017 Hepatitis C Community Summit – a key step on the road to elimination

    In the lead-up to the annual International Liver Congress (ILC) in Amsterdam, Eberhard Schatz of the Correlation Network writes about the Hepatitis C Community Summit that will be held in Amsterdam on the 18-19th of April to focus on community-related initiatives and their key role in the hepatitis C elimination movement. Read more about the Summit and register here.

    4 hours ago | BMC Blogs Network (blog)
  • Gilead hepatitis C drug patent faces European challenge

    International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.

    4 hours ago | Reuters
  • Pharma could take NHS England to court over new delaying tactics

    Pharma and patient groups are dismayed by new cost-capping and delaying measures, which they say will further restrict access to new medicines in England.

    10 hours ago | PharmaPhorum
  • Optimism About HCV Treatment Comes With Caveats

    Despite significant advances in treatment for individuals with HCV infection, several important issues prevail in this patient population.

    22 March 2017 | Medscape
  • Drugs costing 8p a day could be hit by 'devastating' NHS rationing plan

    At present, the NHS has 90 days to make drugs available to patients, once they have been given the green light by the National Institute of Health and Care Excellence (Nice). The new system will allow health officials an extra three years to introduce drugs, during which time they will try to negotiate cost reductions.

    16 March 2017 | Telegraph
  • Malaysia: MOH to propose importing generic Hepatitis C meds

    The Health Ministry will table a working paper to the Cabinet committee for approval to import of generic drugs to treat Hepatitis C.

    14 March 2017 | Malay Mail Online
  • Hepatitis C patients and nurses highlight impact of the virus in new reports

    The reports, titled Patient Perspectives and Nurses' Perspectives, were written after a series of interviews with patients and an online survey with nurses, and lay bare not only the reality of how treatment rationing affects patients and nurses, but also the stigma, fear and isolation still felt by many people living with hepatitis C.

    07 March 2017 | Hepatitis C Trust
  • 'I bought hepatitis C cure from Bangladesh'

    Zoe Sharam bought a hepatitis C cure, deemed too expensive for her by the NHS, online from Bangladesh. She speaks to the BBC's Victoria Derbyshire programme.

    02 March 2017 | BBC Health
  • Hepatitis C drugs re-energize global fight over patents

    The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits were filed in India and Argentina claiming that the latest class of antiviral drugs does not warrant the 20-year patent monopoly that manufacturers have sought in those countries.

    01 March 2017 | Nature
  • Ukraine signs amicable agreement with Gilead on hepatitis C drug

    Ukraine has signed an amicable agreement with U.S. Gilead Sciences, Inc. biopharmaceutical company on the Sovaldi medicine used to treat chronic hepatitis C infection in adults, acting Ukrainian Health Minister Ulana Suprun said at a press conference on Wednesday. The whole course of hepatitis C treatment with the use of Sovaldi in Ukraine will cost about $750.

    27 February 2017 | Interfax Ukraine
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.